model. 1,[4][5][6][7] In particular, the value of AUC is estimated not only over the follow-up duration of the trial but also over The analysis of published survival curves can be used the period following its closing date (using, for this latter as the basis for conducting cost-effectiveness analyses in purpose, a curve extrapolation technique which is based on which two treatments are compared in terms of cost per the survival trend observed during the trial). life year saved. In patients with relapsed chemosensitive
Materials and methods
patient) and multiplying this cost source by its frequency, we estimated that radiotherapy implied, on average, a cost per patient of $1000. The total cost per patient in Study design the transplantation group was therefore $41 000 Our study was designed to conduct a cost-effectiveness ($41 000 = $40 000 + $1000). analysis of the clinical data reported in the randomised trial As regards the conventional treatment group in Philip's of Philip et al. 10, 11 Our evaluation, which employed a novel study, these patients received four courses of DHAP 'lifetime' methodology relying on least-squares Gompertz chemotherapy plus radiotherapy when needed, both given fits (see below), utilised the survival data reported by Philip on an inpatient basis. Uyl-de Groot et al estimated that the et al 10, 11 and the cost data previously determined by Uylcost of four cycles of DHAP chemotherapy was around de Groot et al. 13, 14 These survival and cost data were ana-$12 716 per patient. In Philip's study, radiotherapy was lysed to estimate the cost per life year gained using ABMT given to 22% of the control patients. Considering involvedas compared to standard salvage chemotherapy.
field radiotherapy as an additional source of cost and Because our analysis was based on an incremental design assessing this cost source according to its frequency, we (ratio of incremental cost and incremental effectiveness, estimated that radiotherapy implied an average cost where incremental cost is the cost difference between the per patient of $550. The total cost per patient in the transplantation group and the standard chemotherapy group conventional treatment group was therefore $13 266 and incremental effectiveness is the difference between the ($13 266 = $12 716 + $550). life-years totalled in the transplantation group and the lifeyears totalled in the standard chemotherapy group), our cost
Clinical data included in the analysis evaluations considered only the post-randomisation period and, in this period, only the cost sources that differed
We used the clinical data reported in Philip's trial. 10, 11 This between the two groups being compared.
randomised study assigned 55 patients to receive ABMT In cost-effectiveness analysis, the particular costs and and 54 controls to receive standard chemotherapy (four benefits vary with the perspective of the study, and the courses of DHAP). Survival was the main clinical end-point analysis can in fact be constructed to reflect the viewpoint of the study. The median duration of follow-up was 63 of society as a whole, payers, health care providers, or months. The last time-point in the graph of the survival patients. In the present study, costs were assessed from a curves was at about 75 months. social perspective and were considered to reflect only the expenditure of health care resources (ie direct costs), not
Cost-effectiveness analysis indirect expenses such as wages or productivity lost because of illness or death. This approach is the most comOur analysis proceeded through the following phases: monly used in the analyses published to date.
(1) Estimates were determined of the costs for treating 100 patients with either ABMT or conventional chemoCost data included in the analysis therapy on the basis of the cost data reported above. In particular, in this phase of our analysis the incremental Uyl-de Groot et al 13, 14 estimated that ABMT implies, on average, a treatment cost per patient ranging from $32 000 cost for the ABMT group (100 subjects) was estimated as the difference between the costs of 100 patients (or $40 220 if also pre-transplantation costs for bone marrow harvest, cryopreservation, etc are considered) 13 to given ABMT minus the costs of 100 patients given conventional therapy. $37 500.
14 These estimates included the following sources of cost: bone marrow harvest, outpatient visit, hospitalis-(2) The survival curve of patients who received ABMT ( Figure 2 of the paper by Philip et al) was analysed ation, laboratory services, medical procedures, medication and nutrition, transfusions, etc. and the actuarial percentages of survival at the various time-points of the follow-up were determined from the In our analysis, we assumed that the cost of ABMT was $40 000 per patient. We accepted this estimate (virtually published graph. These survival percentages were used to calculate the total area under the survival curve from identical to the data published by Uyl-de Groot) despite the difference in the conditioning regimen between the study zero time to infinity using a weighted least-squares procedure of survival curve-fitting according to the of Uyl-de Groot (who used TBI) and that of Philip (who used BEAC as conditioning therapy). In other words, we Gompertz function 1,4-7 (see below). This total area (Figure 1 ) was estimated as the sum of the area directly disregarded the type of conditioning regimen as a potential source of cost difference. This approximation is, in our measured in the trial (ie area from zero time to the last time-point of the follow-up) plus the extrapolated right view, acceptable if one considers that, in ABMT, the great majority of costs derive from hospitalisation, bone marrow tail (ie area from the last point of the follow-up to infinity). The value of total AUC in the ABMT is harvest, cryopreservation, reinfusion of marrow cells, etc, whereas the type of conditioning regimen gives a small denoted as AUC ABMT . (3) The survival curve of patients of the control group contribution to total costs. 13, 14 In Philip's study, radiotherapy of the involved field was (published in Figure 2 by Philip et al) was analysed by the same procedure described for patients given given to 40% of the patients undergoing ABMT. Considering this additional source of cost (unit cost = $2500 per 20
ABMT. In this case, the estimation yielded the value of AUC controls . administrations of radiotherapy; total dose = 26 Gy per counting future costs (see below). Hence, this latter sensitivity analysis considered short-term data as the only source of incremental costs.
Our assumption of equivalence of follow-up costs between the two patient groups finds a substantial confirmation in the economic study by Uyl-de Groot 14 in which the follow-up costs over 8 years were estimated as $15 837 per patient in the ABMT group and $12 436 per patient in the conventional chemotherapy group (CHOP protocol) with a saving of $3401 per patient in favour of the latter. Our primary analysis disregarded this difference, whereas our first sensitivity analysis (see below) included these data as a source of further cost difference. conventional chemotherapy was CHOP (and not DHAP as in Philip's study). Despite these differences, our first sensitivity analysis utilised the follow-up cost data of Uyl-de (4) The incremental clinical benefit derived from ABMT Groot and included them in our estimation of incremental was calculated as the difference of AUC ABMT minus cost. Taking 100 subjects, these follow-up data suggested AUC controls (corrected for the different size of the two that the incremental cost of ABMT vs conventional therapy patient groups and normalised to a population of 100 should be increased by a further $340 100. Our first sensipatients). This difference is an estimate of the number tivity analysis recalculated the cost-effectiveness ratio using of patient years gained every 100 patients using ABMT this modified estimate of incremental cost. rather than conventional chemotherapy.
A second sensitivity analysis was carried out exclusively (5) The incremental cost-effectiveness ratio (expressed on using the AUC values from 0 to 75 months and the basis of the cost per life year gained) was calculated disregarding the two extrapolated tails. The incremental by dividing the incremental cost by the incremental cost-effectiveness ratio was recalculated using these AUC benefit.
values.
In a third sensitivity analysis, the survival advantage of Details on the methodology used for least-squares surpatients given ABMT vs control patients (ie the number of vival curve fitting and for AUC estimation are presented in patient-years gained using ABMT as opposed to salvage the Appendix. All mathematical calculations were carried chemotherapy) was expressed in terms of upper and lower out using a specific microcomputer program. 15 The leastlimits of its 95% confidence interval (95% CI). The costsquares fitting subroutine was based on the algorithms of effectiveness analysis was rerun using these two extreme a commercial pharmacokinetic program (PCNONLIN Vervalues of effectiveness. sion 4.0; Scientific Consulting, Burnside Drive, Apex NC-27502, USA).
In our analysis, we assumed that long-term follow-up Discounting clinical and economic data costs were identical between the two patient groups and that ABMT was the only source of (short-term) incremental
In cost-effectiveness analysis, conventional practice 16 suggests discounting either costs alone or both costs and benecosts. In other words, our model of analysis assumed that costs incurred by patients experiencing a relapse were part fits using an annual discount rate of 5%. In our study, we planned to introduce an annual discount rate of 5% into of their terminal care and that terminal care costs did not differ as a consequence of the type of terminal illness both costs and benefits (ie survival).
As regards costs, short-term costs related to ABMT or (which could be either NHL or other non-cancer diseases or even another type of cancer). The reason this scenario salvage chemotherapy were thought to occur exclusively during the first year of the patients' follow-up. Considering was tested is that costs related to terminal care are relatively unpredictable, and one cannot anticipate the effect on terthe customary practice of discounting costs at yearly intervals, there was consequently no need to discount costs in minal-illness costs produced by the cure of a relapsed NHL (achieved hopefully several years or decades before death this analysis.
In our first sensitivity analysis, long-term follow-up costs for a different cause). Another reason why terminal care costs were omitted from our incremental analysis is that derived from Uyl-de Groot et al already contained a 5% annual discount rate and were therefore subjected to no cost differences between the two patient groups, if present, are reduced markedly by the customary practice of disfurther discounting. centile of the treatment group estimated directly from our extrapolated curve). This means that our extrapolations The treatment cost of 100 patients given ABMT was estiassumed that a small subgroup of Philip's patients mated as $4 100 000. The same figure for patients receiving (presumably the youngest subgroup) survived for a total conventional chemotherapy was $1 326 000. Using these of 6 + 49 = 55 years after enrollment. This assumption is data, the incremental cost of ABMT compared with conconsistent with the lower extreme of the age range reported ventional chemotherapy was $2 773 400 every 100 subjects.
by Philip: in fact, individuals aged 24 years or slightly more are likely to survive for a further 55 years, ie until the age Survival curve fitting of 79 years, at least as regards cases who achieve cure. It should be stressed that the biases resulting from these In our analysis of the survival curves of the two patient extrapolations, if any, affected the two curves to the same groups, we first estimated the survival percentages from the extent and were therefore likely to exert no substantial published graph (Table 1) . Then we carried out the leastinfluence on our incremental analysis. squares curve fitting procedure, the results of which are summarised in Table 2 . It should be stressed that the fit was satisfactory for both curves (as demonstrated by the Cost-effectiveness ratio relatively low RMSE values). Extrapolated right tail (which Using 5% annual discount for both costs and benefits, the is, by definition, estimated less precisely) gave a relatively incremental cost-effectiveness ratio was $9229 per dissmall contribution to the total AUC value in the survival counted life year gained. The corresponding value using curve of the controls (32.9%). The extrapolated tail was, in no discounting of benefits was $4623 per undiscounted life contrast, more than 50% of total AUC of the survival curve year gained.
Table 2
Results of survival curve fitting of the data of the two patient groups Figure 2 Survival curves for the bone marrow transplantation group (circles) and the control group (triangles) with extrapolation to infinity. tion must be characterised by using a large number of decimal digits. 7 
Sensitivity analysis
Refs 5, 6 and 15) has allowed use of the experimental data from the first portion of a survival curve as a key element In the first analysis, after adding $340 100 to our previous to predict the course of the curve after the closing date estimate of incremental cost ($2 773 400), the cost-effecof the trial; this approach is clearly preferable to previous tiveness ratio was re-estimated as $10 361 (discounted dolmethods employing more or less arbitrary forms of survival lars per discounted life year gained) or $5190 (discounted curve extrapolation. 17 dollars per undiscounted life year gained). The present study describes a typical application of this The second sensitivity analysis (in which the two new methodology of cost-effectiveness analysis based on extrapolated tails of AUC were not included in the pharmathe lifetime evaluation of survival data. The therapeutic coeconomic calculations) gave an incremental cost-effecissue addressed by our analysis was particularly suitable tiveness ratio of $28 890 per discounted life year gained or for applying this new technique because a recent controlled $24 616 per undiscounted life year gained.
clinical trial was available in which the two treatment The third sensitivity analysis was conducted as follows:
options (ie ABMT and conventional salvage chemotherapy) Philip et al 11 reported that the overall death risk for patients had been specifically compared. given standard chemotherapy was 1.90 (95% CI of 1.33-Our results showed that the cost-effectiveness of ABMT 2.47) in comparison with subjects given ABMT (who were in selected patients with relapsed chemosensitive NHL is assumed to have a risk equal to 1). An approximate method very favourable ($9229 per discounted life year gained or for redetermining this risk value using the AUC data pro-$4623 per undiscounted life year gained). While acceptable duced by our study is to calculate the ratio of the two AUCs figures of cost per life year gained are generally thought to of the two patient groups (which is 7806/4200 = 1.86 lie below the limit of $50 000 (eg Refs 1-6), our data indiaccording to our discounted results presented in Table 2 or cate that, in patients with NHL selected according to the 12 468/5269 = 2.37 according to the corresponding undisprotocol of Philip et al, ABMT implies a relatively low counted data). In this third sensitivity analysis, we kept cost per life year gained. Our sensitivity analyses confirmed unchanged the value of 4200 discounted patient-months for that the upper limits for the cost per life year gained always the control group and we estimated the two extreme values remained below this cut-off value. In the light of the most of AUC for the treatment group (lowest and highest) so recent methodological trends in the area of pharmacoecothat these two values gave, respectively, an AUC ratio of nomics, 18 this confirmation was particularly important. 1.33 and 2.47 (ie the same values as the two extremes of One limitation of our study was the modest degree of the 95% CI of Philip). The results of this calculation were goodness of fit resulting from the application of the Gomas follows: 5586 patient-months (lowest value) and 10 374 pertz model (see Figure 2 and the RMSE values of patient-months (highest value). The corresponding esti- Table 2 ). Goodness of fit was not excellent due to the presmates of incremental effectiveness were 1386 discounted ence of a high short-term mortality (particularly in the patient-months and 6174 patient-months every 100 patients, ABMT group), which in turn translated into an atypical respectively. Using these latter two values, the result of our shape of the survival curves with some consequent fitting calculations was that the two extreme values for cost per problems. Another drawback was the relatively short durdiscounted life year gained using ABMT were $24 012 and ation of the follow-up which kept the ratio between meas-$5390, respectively. These two limits identified a sort of ured AUC vs extrapolated AUC within a suboptimal range 95% CI for the value of cost per discounted life year saved (particularly in the ABMT group). ($9229) produced by our primary analysis.
After the lifetime study on tissue plasminogen activator These calculations were repeated to identify a 95% CI published by Mark et al, 1 which has been an important for the cost per undiscounted life year gained of our primodel for future research, other pharmacoeconomic investimary analysis (ie $4623). In this case, after keeping gations have been carried out using the Gompertz model. unchanged the value of 5269 patient-months for the control
In particular, a number of antineoplastic treatments have group, the resulting two extreme values of cost per undisbeen evaluated by this lifetime methodology, thus providcounted life year gained using ABMT were $19 138 and ing a preliminary series of reference values in terms of cost $4297, respectively. These two limits suggested a range per life year gained. For example, a low cost per life year ($4297-$19 138) for the 95% CI of the cost of $4623 gained has been found for several antineoplastic treatments produced by our primary analysis.
such as adjuvant CMF chemotherapy in node-positive breast cancer (cost per life year gained = $1505) 5 or taxol + cisplatin as first-line treatment for advanced ovarian Discussion cancer (cost per life year gained = $17 000). 4 Other antineoplastic treatments have, in contrast, demonstrated a much worse pharmacoeconomic attractiveness (eg interferon as Cost-effectiveness analyses based on the end-point of 'gain in life years' are increasingly used particularly in the area maintenance therapy in chronic myeloid leukaemia; cost per life year gained = about $100 000). 4 In the context of of oncologic treatments (eg Refs 4-6). An advantage of these analyses is that they invariably employ a 'hard' endthe increasing body of data obtained through the Gompertz methodology, the present study showed that the use of point (ie mortality). Another advantage is that this methodology can easily compare clinical problems between differ-ABMT in selected NHL patients has a favourable costeffectiveness profile despite the well-known high costs of ent therapeutic areas.
The recent implementation of least-squares curve-fitting this form of therapeutic intervention. The study by Uyl-de Groot et al 14 evaluated costs and computer programs based on the Gompertz function (eg effectiveness of ABMT, as opposed to CHOP chemoNevertheless, the study by Barr et al gives a preliminary indication of the cost-effectiveness ratio of allogeneic transtherapy, in patients with intermediate or high-grade relapsed NHL. The clinical information on which these plantation in acute myeloid leukaemia in second complete remission and in acute lymphoblastic leukaemia in first authors based their economic analysis was, however, strikingly different from that utilised in ours. Because Uyl-de remission, which can be a useful reference value even for the results concerning ABMT in NHL obtained in the Groot et al observed no significant survival difference between this unselected use of ABMT vs conventional salpresent study. vage chemotherapy, their economic analysis was in fact a cost-minimisation study in which the crucial point was to establish which of two equi-effective treatments was less
